Results 171 to 180 of about 311,944 (266)

CEACAM1 participation in breast cancer progression

Molecular Oncology, EarlyView.
In invasive breast cancer (BC), CEACAM1 shifts from an apical to a uniform membranous/cytoplasmic pattern, or is lost, as tumors dedifferentiate, inversely tracking the Ki‐67 proliferative index. In MCF‐7 cells, only CEACAM1‐4L suppresses proliferation, repressing cell cycle and growth factor genes.
Mykola Lyndin, Irina Kube‐Golovin, Anatolii Romaniuk, Gunther Wennemuth   +3 more
wiley   +1 more source

Linking Lipidomics to Vulnerable Coronary Plaques: A PROSPECT II Substudy. [PDF]

Arterioscler Thromb Vasc Biol
Sharma T, Fall T, Sayols-Baixeras S, Maehara A, Maeng M, Kjøller-Hansen L, Engstrøm T, Ben-Yehuda O, Matsumura M, Fröbert O, Persson J, Wiseth R, Larsen AI, Smith JG, Engström G, Ärnlöv J, Borén J, Khamis RY, Tsimikas S, Koul S, Rylance R, Ali ZA, James SK, Stone GW, Erlinge D.   +24 more
europepmc   +1 more source

Prospect-refuge patterns in Frank Lloyd Wright's prairie houses: using isovist fields to examine the evidence

It has been argued that the domestic works of Frank Lloyd Wright possess an innate phenomenological appeal that is a direct result of a particular spatial and visual pattern in Wright's architecture.
Michael Dawes (21268016), Michael J. Ostwald (14057933)   +1 more
core  

Pharmacological chromatin remodeling enhances response to estrogen therapy in ER+ breast cancer

Molecular Oncology, EarlyView.
Estrogen therapy elicits clinical benefit in ~ 30% of patients with endocrine‐resistant estrogen receptor (ER)‐positive breast cancer. Based on findings that ER transcriptional activation underlies response to estrogen therapy, we tested the effects of epigenetic dysregulation via pharmacological inhibition of histone deacetylases (HDACi).
Anneka L. Johnson Thomas, Barbara Karakyriakou, Patricia C. Muskus, Alyssa M. Roberts, Justin Rendleman, Alexa Warren, Hanxu Lu, Kimberly A. Birmingham, Malone K. Friedman, Abigail E. Goen, Huijuan Yang, Owen M. Wilkins, Fred W. Kolling, Eugene Demidenko, Julie M. Jorns, Brock C. Christensen, Todd W. Miller   +16 more
wiley   +1 more source

Safety and effectiveness of voxelotor in individuals with sickle cell disease in the RETRO and PROSPECT US registries. [PDF]

Blood Adv
Andemariam B, Shah N, Ershler WB, Ivy ED, Darbari DS, Anderson A, Rai P, Wun T, Yu CR, Purdie DM, Valenzuela CM, Xu M.   +11 more
europepmc   +1 more source

Somatostatin receptor 4 (SSTR4) is a tumor suppressor in cutaneous and head & neck squamous cell carcinomas

Molecular Oncology, EarlyView.
This study identifies somatostatin receptor 4 (Sstr4) as a critical tumor suppressor against skin and head/neck cancers (HNSCC, cSCC, and BCC). The loss of Sstr4 removes a check on cell growth, causing hyperactivation of the MAPK‐ERK signaling pathway (↑).
Ali Taqvi, Tuan Khang Huynh, Adway Kadam, Zahra Kardan, Yue Yan, Amina Jamal Laham, Sampath Kumar Loganathan   +6 more
wiley   +1 more source

3-Year Outcomes of Low-Dose vs High-Dose Drug-Coated Balloons in Femoropopliteal Artery Disease: The PROSPECT MONSTER Study. [PDF]

JACC Adv
Nakama T, Takahara M, Iwata Y, Suzuki K, Tobita K, Hayakawa N, Horie K, Mori S, Obunai K, Ohki T, PROSPECT MONSTER Study Investigators.   +10 more
europepmc   +1 more source

Castration‐resistant prostate cancer cells are addicted to the high activity of cyclin‐dependent kinase 2

Molecular Oncology, EarlyView.
We show that emergence of castration‐resistant prostate (CRPC) is associated with significant upregulation of cyclins that positively regulate cyclin‐dependent kinase 2 (CDK2) and concomitant downregulation of CDK4 cyclins. This renders CRPC cells dependent on the high activity of CDK2, and CDK2 inhibitors synergistically sensitize CRPC cells to both ...
Joyeeta Chatterjee, Alessia Marin, Shivani Yalala, Harri M. Itkonen   +3 more
wiley   +1 more source

IRB Policies on the Inclusion of Pregnant Women in Research. [PDF]

Ethics Hum Res
Morain SR, Propes C, Faden RR.
europepmc   +1 more source

Partial FAK suppression promotes tumor growth, an effect reversed by macrophage p110δ PI3K inactivation

Molecular Oncology, EarlyView.
Partial inhibition of focal adhesion kinase (FAK) can paradoxically promote tumor growth, rather than simply producing a weaker antitumor effect than that observed with strong FAK suppression. In breast cancer and melanoma models, targeting p110δ PI3K, particularly in macrophages, counteracted these tumor‐promoting effects, highlighting the importance ...
Lydia Xenou, Niki Tzenaki, Anna Tsapara, Maria Tzardi, Evangelia A. Papakonstanti   +4 more
wiley   +1 more source